For this reason, bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEG-F) is effective for ascites reduction [35], but this drug also has a significant toxicity profile including severe hypertension and bowel perforation that often precludes its use. Here, VEGFA is linked to Hypertension.